Redhill Biopharma Ltd (RDHL) FinancialsRDHLRedhill Biopharma Ltd

Redhill Biopharma Ltd (RDHL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial operations, accounting for 55.4% of total sales, equivalent to $7.10M. Another important revenue stream is Research and Development. Understanding this composition is critical for investors evaluating how RDHL navigates market cycles within the Pharmaceuticals industry.

In the context of the broader market, RDHL competes directly with industry leaders such as ONCO and LIMN. With a market capitalization of $3.82M, it holds a significant position in the sector. When comparing efficiency, RDHL's gross margin of N/A stands against ONCO's 25.13% and LIMN's N/A. Such benchmarking helps identify whether Redhill Biopharma Ltd is trading at a premium or discount relative to its financial performance.

Redhill Biopharma's financial performance is concerning, with a gross margin of 100.00% reported in Q2 2025, but this is overshadowed by a net income of -2066500.00 USD for the same period. The company's total revenue for Q2 2025 was only 2039499.00 USD, which is insufficient to cover its losses, leading to a negative net margin of -1026.22%.